{"entity":{"id":"idp-004","kind":"drug","name":"IDP-004","aka":[],"tldr":"IDP-004 is an experimental bispecific antibody-drug conjugate from InduPro Therapeutics, in preclinical development for cancer.","summary":"IDP-004 is a bispecific antibody-drug conjugate from InduPro Therapeutics. A bispecific antibody-drug conjugate against MET and an undisclosed partner antigen the company calls TAPA-M1. Its furthest stage is preclinical development, for cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline chart bar ends in the lead-optimisation column (HTML data-width 48); no registered trial found. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"InduPro Therapeutics: induprotx.com","url":"https://www.induprotx.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["met"],"drugs":[],"companies":["indupro-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IDP-004","modality":"Bispecific antibody-drug conjugate","mechanism":"A bispecific antibody-drug conjugate against MET and an undisclosed partner antigen the company calls TAPA-M1.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/idp-004/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"indupro-therapeutics","kind":"company","name":"InduPro Therapeutics","route":"/companies/indupro-therapeutics/"}]}}